Some graphs are self explanatory. And some hypothesis are practice changing in place where drug acess and financial toxicity is reality. Atul Batra ESMO - Eur. Oncology Sara Tolaney Yakup Ergün Erika Hamilton, MD, FASCO OncoAlert

Explaining World championship to my friends. It’s simple guys…

Congratulations 👏 . ✨ Dr. Sudeep Gupta and team Tata Memorial Hospital deliver the first phase III trial showing OS benefit with carboplatin in TNBC (JCO 2025, n=717). Overall (ITT population): 📈 5-yr EFS: 70.7% vs 64.1% (HR 0.80, p = 0.081) 💫 5-yr OS: 74.4% vs 66.8% (HR 0.74, p =

🫁 Sequential therapy for advanced/metastatic #EGFRm #NSCLC 🫁 🫁 I’ve compiled it into a table. (PFS & OS only) 🌟 After #ESMO25 🌟 OptiTROP-Lung04 (Sac-TMT) & Iza-bren (BL-B01D1) mono-therapy were added. ⚠️ For reference only ⚠️ #lungcancer #nsclc #egfr #LCSM

4 upcoming Vande Bharat routes Tap👇

Just out in NEJM Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 Luciano J Costa marivi mateos Link: nejm.org/doi/full/10.10… More in thread

Highlights from #ASH25 #CommunityOnc: #Lymphoma 1. #EPCOREFL1 FL 2. #CLL17 CLL 3. #BRUIN313/314 CLL 4. #S1826 HL #Myeloma 5. #COBRA 6. #MajesTEC3 7. #AQUILA 8. #RedirecTT1 #Leukemia 9. #PARADIGM ASH #lymsm #mmsm #HemeTwitter 1/10

TDXd + Pertuzumab now U.S. FDA ✅ in 1L metastatic Her2+ breast cancer based off #DestinyBreast09: vs THP: - mPFS 40.7 vs 26.9mos (HR: 0.56) - 15.2% vs 8.5% CRs - Serious TAES: 27% vs 25.1%. Any Gr ILD 12.1% vs 1%. 2 Gr5 ILDs! #OncTwitter #bcsm OncoAlert OncUpdates

💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0: 📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower

Veer Baal Diwas is a day of reverence, dedicated to remembering the sacrifice of the brave Sahibzades. We recall the unshakeable faith of Mata Gujri Ji and the immortal teachings of Sri Guru Gobind Singh Ji. This day is associated with courage, conviction and righteousness. Their

Honored by the invitation from Atul Batra & the organizing committee of the AIIMS, New Delhi 🇮🇳 2nd Annual #UroOncology Updates meeting (Aparna Sharma Ranjit Kumar Sahoo Brusabhanu Nayak 🇮🇳 & #DrAkashKumar). Looking fwd to joining Neeraj Agarwal, MD, FASCO Petros Grivas & Ashish M. Kamat, MD, MBBS for what looks to be a

Trastuzumab Deruxtecan (+Pertuzumab) is now U.S. FDA ✅in 1L Her2+ mBC off #DestinyBreast09! We 🗣️ this trial, findings, maintenance phase, & AEs w/ Sara Tolaney Full 🗣️: ⭐️On OncBrothers & OncUpdates Website ⭐️Also on “Oncology Brothers” podcast OncUpdates #bcsm #OncTwitter

The Hodgkin Lymphoma Prognostic Score (IPS) is taught as 7 unrelated risk factors. That’s misleading. IPS is really a snapshot of the Reed–Sternberg cell’s inflammatory output 🏭🔥 Albumin ↓ Hb ↓ ↳ IL-6 flooding the system, acute phase response, hepcidin on overdrive WBC ↑

I have absolutely no fucking idea how and when this whole segregation between Punjabi Hindus and sikhs happened . Yes , Sikhs are not Hindus and Punjabi Hindus are not Sikhs but there is an intersection that’s beautiful . Most Punjabi Hindus believe in both guru Nanak and Hindu

Mr Mayor Zohran Kwame Mamdani, I say it as an Iranian New Yorker: You are a human garbage. When our people were getting slaughtered and hunted like animals by the Islamic Republic terrorists, you stayed silent. You didn't say a word. Now that the regime, the murderers of our people are under

This changes how we approach first relapse. In Dara sensitive patients: Tec-Dara or Cilta-cel are the top two choices. If Dara refractory: Bispecifics alone or Cilta-cel are the main options. CART and Bispecifics both need close monitoring and specialized care and certain

Papa's Pod is finally coming back! This is a hematology podcast with a focus on clinical care (not just data) and what you actually have to know to care for patients! I plan to do one episode a week (first will be CART in myeloma) and open to requests! podcasts.apple.com/us/podcast/pap…

Finally, police in India doing what they should have done decades ago - heavy fines for traffic violations. This motorcyclist got a ₹40,000 ticket for multiple violations - no DL, no insurance, no PUC, no helmet, pressure horn and non functional silencer. His neighbours will be

Weird medical decision making in the final episode of the Pitt 1. Using diazepam instead of lorazepam in status epilepticus. The latter is probably superior. Probably should have used more mag too. 2. They delayed intubation until she was clearly in status. I get waiting a

India’s weight-loss drug market just ran a live experiment in price elasticity. Novo Nordisk’s semaglutide patent expired 20 March 2026. Within 3 weeks: 15+ generics launched Cheapest at Rs 2,000/month (branded was Rs 10,000+) Novo cut Ozempic and Wegovy prices by 36-48%